

Index

A

- aCGH. *See* Array comparative genomic hybridization
- AKT. *See* Protein kinase B
- ALSA. *See* Antibody-lectin sandwich array
- Angiogenesis
 - biomarkers, 280, 281
 - therapeutic target, 280
 - VEGF, 279
- Anti-angiogenesis efficacy, gemcitabine, 65–67
- Antibody-lectin sandwich array (ALSA), 256.
 - See also* Protein glycosylation
 - affinity-based methods, 255, 257
 - core protein and glycan levels, 258
 - glycans role, 244
 - low-volume, high-throughput sample processing, 258
 - multiplexing capability, 257
 - in research
 - cancer cell subpopulations, 261
 - cyst fluid biomarkers, 261
 - immunotherapy, targets for, 262
 - model systems, 259
 - population variation of, 259
 - protein carriers, 260
 - serum biomarkers for, 260
- Apoptosis, 18
- Array comparative genomic hybridization (aCGH)
 - candidate genes selection, 148
 - data analysis, 139, 140
 - fluorescence in situ hybridization (FISH), 147
 - genome alteration
 - copy number in, 136, 137
 - cytogenetics, 136

- and platform comparison
 - alterations detection, papers published on, 138
 - BACs, 137
 - cDNA sequence clones, 137, 139
 - ROMA, 139
- promoter methylation, 148
- samples analysis and findings
 - factors, 140
 - frequency of, 141, 147
 - minimal common region alteration, 142–146
 - standard approach, 148
- Aurora A kinase, 214, 215

B

- Bacterial artificial chromosomes (BACs), 137
- Bevacizumab, 235, 236
- Biomarkers
 - angiogenesis, 280, 281
 - definition, 271, 272
 - DNA microarray, 124, 125
 - mouse xenograft models
 - deoxycytidine kinase, 41, 42
 - fine-needle aspiration biopsy (FNAB), 43
 - pharmacodiagnostic marker, 41
 - tailor-made treatment process, 42
 - personalized therapies and predictive markers, 41–43
 - prêt-à-porter treatments, 44
 - tailor-made treatments, 43, 44
 - proteomic analysis
 - EGFR pathway, 233, 234
 - VEGF pathway, 235, 236
- Blood group structures, 253, 254

C

- Cancer progression, glycans' role
 - cell adhesion and metastasis, 249, 250
 - immunomodulation, 250, 251
- Cancer stem cells (CSCs), 5
- Carbohydrate antigen (CA) 19-9 factor, 278, 279
- Cell cycle parameters, 21, 22
- Circulating endothelial cells (CEC), 281
- Circulating tumor cells (CTCs), 283, 284
- Cyclooxygenase-2 (COX-2), 281, 283
- Cyst fluid biomarkers, 261
- Cytidine deaminase activity (CDA), 276, 277
- Cytogenetics, aCGH, 136

D

- Deoxycytidylate deaminase (DCTD), 276, 277
- Diffuse large B-cell lymphoma (DLBCL) cell lines, 162
- DNA methylation, epigenomics
 - biomarkers of, 193, 194
 - CpG nucleotide, 187–189
 - hypermethylation, 191, 192
 - hypomethylation, 189–191
 - mechanisms, 189
 - promoter hypermethylation, precursor lesions, 192, 193
- DNA microarray, profiling
 - gene expression platforms
 - affymetrix arrays, 116
 - cDNAs, 114
 - oligonucleotide arrays, 115
 - overview of, 115
 - technical considerations, 116
- Drug evaluations, culture systems
 - cell types
 - advantages, 6, 7
 - cell lines, 3, 4
 - insulin-secreting cell lines, 4
 - limitations, 7
 - normal cells, 2, 3
 - rodent pancreatic cancer, 4
 - stem cells, 5, 6
 - co-culture, 8
 - 3D cell culture, 8
 - dish cultures, 7, 8
 - HTS, 9
 - in vitro analyses
 - apoptosis, 18
 - cell cycle parameters, 21, 22
 - cell proliferation, 18, 19
 - cell viability, 20, 21

- DNA synthesis, 19, 20
- invasive/metastasis, 22
- pharmacotherapeutic applications
 - AKT, 12, 13
 - cell cycle, 18
 - JAK/STAT pathway, 10
 - MAPK, 10
 - NF- κ B, 16–18
 - PI₃K family, 11, 12
 - protein kinase C (PKC), 11
 - receptor tyrosine kinases (RTKs), 13–15
 - signal transduction pathways, 9
 - VEGF, 15, 16

E

- Endothelial precursor cells (CEP), 281
- Epidermal growth factor receptor (EGFR), 233, 234
- Epigenomics. *See* Methylation detection and epigenomics
- Equilibrative nucleoside transporter 1 (ENT1), 276
- Erlotinib, 14, 234, 279

F

- FFPE. *See* Formalin-fixed and paraffin-embedded tissue blocks
- Fluorescent in situ techniques (FISH)
 - applications of, 219
 - FFPE samples, 219, 220
 - probes, types of, 217, 218
 - steps in, 218, 219
- Fluorescent metastatic mouse models
 - bioluminescent jellyfish (*Aequorea victoria*), 54
 - dual-color models
 - liver metastasis, 67, 68
 - orthotopic model, 65–67
 - GFP models
 - micrometastases, 55
 - real-time whole-body simultaneous images, 57, 58
 - sequential intravital images, 59, 60
 - site-specific metastases, orthotopic models, 55, 57
 - RFP models
 - drug discovery and evaluation, 63–65
 - sensitivity, 61–63
- Formalin-fixed and paraffin-embedded (FFPE) tissue blocks, 206, 207, 219, 220
- Fucose, 254

G

- Gefitinib, 14, 234
- Gemcitabine, 167, 177
 - anti-angiogenesis efficacy
 - CD31, endothelial marker, 66
 - MIA-PaCa-2 pancreatic tumor, 67
 - ND-GFP expression, 66
 - nestin, stem cell marker, 65
 - CA 19-9 factor, 278, 279
 - CDA and DCTD, 276, 277
 - equilibrative nucleoside transporter 1 (ENT1), 276
 - ribonucleotide reductase, 277
 - survivin, 277, 278
- Gemzar™. *See* Gemcitabine
- Gene expression arrays
 - biomarkers, 124, 125
 - cDNA microarray, 113
 - high-throughput analyses, 127, 128
 - microarray data application
 - cancer types reclassification, 117
 - characterization, 117–119
 - classes, identification of, 119
 - drug targets, 121–123
 - expression signatures, cancer subclasses, 119–121
 - signatures, drug discovery tool, 123, 124
 - model organisms, 126, 127
 - profiling, DNA microarray platforms, 114–116
 - technical considerations, 116
- Genetically engineered mouse (GEM) models, 34, 35, 80, 274
- Germ-line zebrafish mutants
 - exocrine pancreas
 - ducttrip* (*dtp*) locus, 104
 - mind bomb* (*mdb*), 101
 - morphogenesis, 103
 - sonic you* (*syu*), 101
 - techniques, 103, 104
- Glycans. *See* *N*-glycans; *O*-glycans
- Green fluorescent protein (GFP) models
 - BxPC-3-GFP cells, 55, 56
 - MIA-PaCa-2 model, 57
 - micrometastases, 55
 - sequential intravital images
 - liver micrometastasis, 60
 - omental micrometastasis, 59
 - site-specific metastases, 57
 - surgical orthotopic implantation (SOI), 56
 - whole-body imaging, 57, 58

H

- Hamster origin cells, 4
- HeLa cervical carcinoma cells, 165
- Heterotransplanted human tumor xenografts, 36, 37
- High-throughput screening (HTS), 9. *See also* RNA interference (RNAi), high-throughput (HT) screening
- Histone deacetylases (HDAC), 186, 187
- Histone methyltransferases (HMTs), 185
- Histone modifications
 - acetylation, 186, 187
 - methylation
 - enhancer of zeste homolog 2 (EZH2), 185, 186
 - histone methyltransferases (HMTs), 185
 - MLL* and *MLL3* genes, 186
- Human origin cells, 4
- Human pancreatic ductal epithelial cells (HPDE), 2, 3
- Human pancreatic nestin expressing cells (HPNE), 3

I

- Immunohistochemistry (IHC), tissue microarrays
 - artifacts, 217
 - Aurora A kinase, 214, 215
 - processing steps, 216
 - SMAD4 protein, 215
- Immunomodulation, glycans' role, 250, 251
- Insulin-secreting cell lines, 4
- Isobaric tags for relative and absolute quantification (iTRAQ), 228
- Isotope-coded affinity tags (ICAT), 226–228

J

- JAK/STAT pathway, 10

L

- Lewis blood group structures, 253, 254
- Liquid chromatography-mass spectrometry (LC-MS/MS), proteomic analysis
 - multiple reaction monitoring (MRM), 230, 231
 - phosphoproteomics, 229, 230
 - stable isotope labelling
 - in vitro, 226–228
 - in vivo, 228, 229
- Liver metastasis
 - experimental model of, 68
 - XPA-1, 67, 69

M

Mannose, 255
 Manual arrayers, 209
 MAP kinase (MAPK), 10
 Maximum tolerated doses (MTD), 88
 MCTP. *See* Murine clinical trials program
 Metastasis and cell adhesion, 249, 250
 Methylation detection and epigenomics
 biomarkers, aberrant DNA methylation patterns, 193, 194
 DNA methylation studies
 CpG nucleotide, 187–189
 hypermethylation, 191, 192
 hypomethylation, 189–191
 mechanisms, 189
 promoter hypermethylation, precursor lesions, 192, 193
 genetic disease
 deleted in pancreatic carcinoma 4 (DPC4), 183
 KRAS2 mutations, 182
 TP53, 182, 183
 genome project, 194, 195
 histone modifications
 acetylation, 186, 187
 methylation, 184, 186
 miRNA, epigenetic regulation, 193
 precursor lesions, 183
 Microarray data
 cancer types reclassification, 117
 characterization, cancer classes
 BRCA2, 118
 data set, 117
 liver/lymph node metastasis, 119
 supervised interrogations, question types, 118
 classes, identification of, 119
 drug targets, differentially expressed genes, 121–123
 expression signatures, cancer subclasses, 119–121
 signatures, drug discovery tool, 123, 124
 unsupervised interrogations, 120
 Microarray technology, 173
 Micro RNAs (miRNAs), 154, 155
 adenocarcinoma, 175, 176
 application of
 gemcitabine, 177
 pain, 178
 bead-based method, flow cytometry, 173, 174
 biomarkers, 175, 176
 characterization, 172
 cloning methods–miRAGE, 174, 175
 differential expression, 176

 epigenetic regulation, 193
 lin-4 and let-7, 172
 microarray technology, 173
 RAKE, 175
 miRNA serial analysis of gene expression (miRAGE), 174, 175
 Mouse xenograft models
 animal models and
 GEM models, 34, 35
 heterotransplanted human tumor xenografts, 36, 37
 humanized mice, 35, 36
 orthotopic tumor models, 32–34
 biomarkers and personalized therapies
 predictive markers, 41–43
 prêt-à-porter treatments, 44
 tailor-made treatments, 43, 44
 classical drug development program
 hollow fibre assay (HFA), 31
 NCI, 30
 sensitive cell lines, 31
 variables and endpoints
 growth characteristics, 38
 mice strain, 38
 pharmacokinetics, 39
 test compounds, 39
 treatment onset, 38
 Multiple reaction monitoring (MRM), 230, 231
 Murine clinical trials program (MCTP), 81

N
 National Cancer Institute (NCI), 30
 Nestin-driven green fluorescent protein (ND-GFP), 65, 66
N-glycans
 β 1-6GlcNAc branching of, 252, 253
 biosynthesis and structures, 245, 246
 functions of, 247
 Nuclear factor-kappaB (NF- κ B)
 anti-apoptotic effects, 17, 18
 mechanism of action, 17

O
O-glycans
 biosynthesis and structures, 247, 248
 functions of, 248
 mucins, core-1 structures, 251, 252

P
 Pancreatic adenocarcinoma cells (PANC-1), 107
 Pancreatic ductal adenocarcinoma (PDA), 74
 Pancreatic intraepithelial neoplasias (PanINs), 77, 182

- Pancreatic stellate cells (PSC), 85
 PDA. *See* Pancreatic ductal adenocarcinoma
 Personalized therapies and biomarkers
 predictive markers, 41, 43
 prêt-à-porter treatments, 44
 tailor-made treatments, 43, 44
 Pharmacodynamic (PD) biomarkers,
 therapeutic evaluation
 angiogenesis-targeting agents
 circulating endothelial cells
 (CEC), 281
 soluble angiogenic proteins, 280, 281
 therapeutic target, 280
 VEGF, 279
 assay validation, 272
 circulating tumor cells (CTCs), 283, 284
 clinical assessment of, 274, 275
 COX-2 expression and inhibition
 celecoxib, 282, 283
 over-expression, 281, 282
 erlotinib, 279
 gemcitabine
 CA 19-9 factor, 278, 279
 CDA and DCTD, 276, 277
 equilibrative nucleoside transporter 1
 (ENT1), 276
 ribonucleotide reductase, 277
 survivin, 277, 278
 genetically engineered mouse (GEM), 274
 hetero-transplanted human xenografts,
 273, 274
 in vitro models, 272, 273
 imaging approaches, 275
 secreted protein acidic and rich in cysteine
 (SPARC), 283
 xenograft models, 273
 Phosphoproteomics, 229, 230
 PI₃K family, 11, 12
 Polyomavirus middle T antigen (PyMT), 252
 Preclinical paradigm
 cell autonomous targets, 82, 83
 complex organ, cancer, 76
 criteria for, mouse model, 82
 human disease, mammalian surrogate
 PanINs, 77
 preinvasive neoplasms, pancreatic
 ducts, 78
 MCTP, 81
 mice modeling role, 78–80
 multi-dimensional analysis, 81
 non-cell autonomous targets
 angiogenesis, 85
 fibroinflammatory response, 84
 immune cells, 84, 85
 PSC, 85
 PDA, lethal disease, 74
 principles
 acquired resistance, 87
 disease detection, 86, 87
 dosing schedules, 88–90
 imaging, 87, 88
 risk factors and chemoprevention, 86
 target inhibition, 87
 translation of, 75
 treatment efficacy, 74, 75
 Protein glycosylation
 cancer progression
 cell adhesion and metastasis,
 249, 250
 immunomodulation, 250, 251
 classes of, 244, 245
 glycan alterations in
 blood group structures, 253, 254
 fucose, 254
 mannose, 255
 mucins, core-1 *O*-glycan structures,
 251, 252
 N-glycans, β 1-6GlcNAc branching of,
 252, 253
 sialic acids, 254
 N-glycans, 245–247
 O-glycans, 247, 248
 structural features of, 245
 Protein kinase B, 12, 13
 Protein kinase C (PKC), 11
 Proteomic analysis, blood and pancreatic
 juice
 biomarkers
 EGFR pathway, 233, 234
 sources of, 225
 VEGF pathway, 235, 236
 catalogue of, 231
 chemotherapy, 232
 gel-based approaches, 232
 quantitative LC-MS/MS approaches
 in vitro, stable isotope labelling,
 226–228
 in vivo, stable isotope labelling,
 228, 229
 multiple reaction monitoring (MRM),
 230, 231
 phosphoproteomics, 229, 230
 SELDI, 232
- R**
 Receptor tyrosine kinases (RTKs)
 classes of, 13
 erlotinib, 14, 15
 gefitinib, 14
 TKIs, 14

- Red fluorescent protein (RFP) models
 CS-682, 63
 gemcitabine, 63
 MIA-PaCa-2-RFP, 64
 sensitivity
 fluorescence optical imaging (FOI), 62
 whole-body optical images, 61
 therapeutic interventions, 65
 tumor fluorescence, 61
- Redundant siRNA activity (RSA) analysis, 159
- Representational oligonucleotide microarray analysis (ROMA), 139
- Ribonucleotide reductase, 277
- RNA interference (RNAi),
 high-throughput (HT) screening
 advantage of, 157, 158
 application of
 Akt activity, 165
 combination therapies, 167
 drug mechanisms elucidation, 166
 gemcitabine, 167
 HeLa cervical carcinoma cells, 165
 MCF-7 cells, 165
 approaches, 154, 155
 assay development (AD), parameters in,
 158
 assay validation (AV), 156
 phases of, 157
 post-screen assessment, 159
 redundant siRNA activity (RSA) analysis,
 159
 siRNA/shRNA targeting, 160
 target identification
 DLBCL cell lines, 162
 functional validation, 162, 164
 kinases, 162
 lethality and synthetic lethality screens,
 160, 161
 publications, 163
SMAD4 gene, 164
 viral vector, 155
- RNA-primed array-based Klenow enzyme
 assay (RAKE), 175
- Robotic arrayers, 209
- ROMA. *See* Representational oligonucleotide
 microarray analysis
- S**
- Secreted protein acidic and rich in cysteine
 (SPARC), 283
- Serial analysis of gene expression (SAGE)
 libraries, 119
- Serum biomarkers, 260
- Short hairpin RNAs (shRNA), 154, 155
- Sialic acids, 254
- Signal transduction pathways
 AKT, 12, 13
 JAK/STAT pathway, 10
 MAPK, 10
 PI₃K family, 11, 12
 PKC, 11
- SMAD4* gene, 164
- Small interfering RNAs (siRNA), 154, 155
- Soluble angiogenic proteins, 280, 281
- Soluble vascular cell adhesion molecule
 (sVCAM-1), 235, 236
- Stable isotope labelling with amino
 acids in cell culture (SILAC),
 226–229
- Stem cells, drug evaluation
 cell surface markers, 5
 CSC, 5
 signaling pathways, 6
- Surface-enhanced laser desorption ionisation
 (SELDI), 227, 232
- Survivin, 277, 278
- T**
- Tarceva™. *See* Erlotinib
- Thomsen–Friedenreich (TF) antigen, 251
- Tissue microarrays (TMAs)
 applications of
 cell line material, 212, 213
 clinical and research settings, 212
 frozen tissue arrays, 211
 composite block, 206
 construction equipment, 209
 construction process, 210
 representation of, 210, 211
 in situ techniques
 estrogen receptor (ER) staining,
 213, 214
 FISH, 217–220
 immunohistochemistry, 214–217
 types of, 208, 209
- Transgenics, zebrafish
 cancer development
 hedgehog pathway, 104
 K-Ras, 105
 TILLING, 106
 genetically engineered model techniques,
 106
- Transplants, zebrafish
 techniques in, 108
 xenograft of, 106–108
- Transtuzumab, 234
- Tyrosine kinase inhibitors (TKIs), 14

V

- Vascular endothelial cell growth factor (VEGF)
 - AZD2171, 236
 - bevacizumab, 235, 236
 - drug evaluations, culture systems, 15, 16
 - vatalinib, 236
- Vatalinib, 236

W

- Wild-type zebrafish
 - exocrine pancreas, 99, 100
 - techniques in, 100, 101

X

- Xenograft models, 273. *See also* Mouse xenograft models

Z

- Zebrafish, target identification
 - germ-line mutants
 - exocrine pancreas, 101–103
 - techniques, 103, 104
 - models and techniques
 - bioinformatics, 99
 - tumor vascularization, 97
 - ultrasonographic imaging, 97, 98
 - visual detection of, 98
 - role of, 96
 - transgenics
 - cancer development, 104–106
 - GEM technique, 106
 - transplants
 - techniques in, 108
 - xenograft of, 106–108
 - wild-type models
 - exocrine pancreas, 99, 100
 - techniques in, 100, 101